Eltrombopag Olamine

Welcome to Dwaey, specifically on Eltrombopag Olamine page.
This medicine contains important and useful components, as it consists of
Eltrombopag Olamine is available in the market in concentration.

Generic Name of Eltrombopag Olamine - Learn More

Eltrombopag Olamine

Eltrombopag Olamine Precaution - What You Need to Know

Before initiating treatment with Eltrombopag Olamine, it is essential for patients to consult their healthcare provider due to the following precautions:

- Liver Function Monitoring: Eltrombopag can cause liver toxicity, and regular monitoring of liver enzymes (such as ALT and AST) is required before starting the medication and periodically during treatment. If significant liver dysfunction is detected, treatment may need to be adjusted or discontinued.
- Risk of Thrombosis: Eltrombopag may increase the risk of thrombotic events (such as deep vein thrombosis or pulmonary embolism) due to the elevated platelet counts it can cause. Close monitoring of platelet counts is essential to avoid complications from excessive platelet aggregation.
- Bone Marrow: Eltrombopag should be used cautiously in patients with a history of bone marrow disorders or myelodysplastic syndromes (MDS), as it may potentially exacerbate these conditions.
- Pregnancy and Breastfeeding: Eltrombopag is classified as Pregnancy Category C, meaning it should only be used during pregnancy if the potential benefits outweigh the risks. It is not recommended during breastfeeding, as it is unknown if the drug is excreted in breast milk. Women of childbearing age should use contraception while taking this drug.

Eltrombopag Olamine Indication - Uses and Benefits

Eltrombopag is primarily used for the treatment of various conditions involving low platelet counts:

- Chronic Immune Thrombocytopenia (ITP): Eltrombopag is used in patients with chronic ITP, a condition where the immune system destroys platelets, leading to a high risk of bleeding. It helps to increase platelet counts and reduce bleeding episodes.
- Severe Aplastic Anemia (SAA): Eltrombopag is used as part of a combination therapy for severe aplastic anemia in patients who have not responded to immunosuppressive therapy.
- Chronic Hepatitis C (HCV): Eltrombopag is used in combination with other treatments to help increase platelet counts in patients with chronic hepatitis C, especially in those with liver cirrhosis, who require interferon-based therapy.
- Myelodysplastic Syndromes (MDS): Eltrombopag may also be used to treat patients with myelodysplastic syndromes (MDS) in whom platelet counts are critically low.

Eltrombopag Olamine Contraindications - Important Warnings

Eltrombopag is contraindicated in the following situations:

- Hypersensitivity: Patients who are allergic to Eltrombopag or any of its components should not use this medication.
- Severe Liver Disease: Eltrombopag is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C), as it may worsen liver function.
- Pregnancy: Eltrombopag should not be used during pregnancy unless absolutely necessary, as its safety during pregnancy has not been well-established, and it may harm the fetus.
- Thrombocytosis: Eltrombopag should not be used in patients who have very high platelet counts (thrombocytosis), as excessive platelet production can lead to complications such as thrombosis.

Eltrombopag Olamine Side Effects - What to Expect

Eltrombopag can cause both common and severe side effects. Patients should be vigilant and consult their healthcare provider if they experience:

- Common Side Effects:
- Headache
- Nausea
- Fatigue
- Diarrhea
- Insomnia
- Upper respiratory tract infection

- Serious Side Effects:
- Liver Toxicity: Symptoms such as yellowing of the skin (jaundice), dark urine, and persistent abdominal pain may indicate liver dysfunction, which requires immediate medical attention.
- Thrombosis: Increased platelet counts can lead to the risk of blood clots. Symptoms of thrombotic events include leg swelling, chest pain, shortness of breath, or sudden weakness.
- Bone Marrow Disorders: Prolonged use may affect the bone marrow and lead to conditions such as myelodysplastic syndrome (MDS) or leukemia.
- Cataracts: Long-term use of Eltrombopag may be associated with the development of cataracts. Eye exams may be required during treatment to monitor for this potential side effect.
- Severe Allergic Reactions: Symptoms such as rash, swelling, and difficulty breathing require immediate medical intervention.

Eltrombopag Olamine Pregnancy Category ID - Safety Information

3

Eltrombopag Olamine Mode of Action - How It Works

Eltrombopag is a thrombopoietin receptor agonist that works by stimulating the thrombopoietin receptor (TPO-R) on megakaryocytes and stem cells in the bone marrow. By activating this receptor, Eltrombopag promotes the production and maturation of platelets from the bone marrow. This process increases platelet counts, which is beneficial for patients suffering from thrombocytopenia (low platelet counts), particularly in conditions like immune thrombocytopenia (ITP), chronic hepatitis C, and severe aplastic anemia.

Eltrombopag’s action is non-hematopoietic, meaning it works directly on the thrombopoietin receptor rather than stimulating the overall production of all blood cells. This specific mechanism of action makes it effective at raising platelet counts without significantly affecting other aspects of the blood cell production process.

Eltrombopag Olamine Drug Interactions - What to Avoid

Eltrombopag has several important interactions that can affect its efficacy or increase the risk of side effects:

- Iron and Calcium: Eltrombopag absorption can be decreased when taken with iron supplements, calcium, or antacids containing divalent cations (such as magnesium or aluminum). It is recommended to take Eltrombopag at least 2 hours before or 4 hours after these products to avoid reduced absorption.
- Warfarin: Eltrombopag may interact with warfarin, an anticoagulant, affecting its efficacy. Regular monitoring of INR (International Normalized Ratio) is needed if these drugs are taken together.
- Corticosteroids and Immunosuppressants: When used in combination with corticosteroids or immunosuppressive drugs, Eltrombopag may enhance the risk of thrombotic events or infection. Careful monitoring of patients for potential complications is required.
- Other Medications: Drugs that affect liver enzymes (like CYP450 inducers or inhibitors) may alter the metabolism of Eltrombopag, affecting its plasma levels. Therefore, patients should inform their healthcare provider about all medications they are taking.

Eltrombopag Olamine Adult Dose - Recommended Dosage

For chronic immune thrombocytopenia (ITP), the usual starting dose of Eltrombopag is 50 mg once daily. If platelet counts are inadequate, the dose may be increased by 25 mg increments up to a maximum of 75 mg daily.

For severe aplastic anemia (SAA), the dose is typically 50 mg once daily. The dose may be adjusted depending on the patient's response and any side effects encountered.

For chronic hepatitis C, the recommended dose is 25 mg daily, which may be increased based on response.

Eltrombopag Olamine Child Dose - Dosage for Children

The safety and efficacy of Eltrombopag in pediatric patients (under 18 years of age) have not been established for most indications. For chronic immune thrombocytopenia (ITP), clinical studies have suggested the use of Eltrombopag in children aged 1 to 17 years, with doses typically starting at 50 mg per day, depending on body weight and platelet response. The dose is adjusted according to the child's weight, with recommendations to avoid exceeding the adult dose limits.

Eltrombopag Olamine Renal Dose - Dosage for Kidney Conditions

Eltrombopag does not require any dose adjustment for mild to moderate renal impairment. However, in patients with severe renal impairment (CrCl < 30 mL/min), careful monitoring is necessary, and the dose should be reduced to avoid potential adverse effects related to accumulation. A healthcare provider will determine the most appropriate dosing regimen for these patients.